Urinary System Carcinoma — Trials

Urinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 670
Recruiting: 353
Ph III recruiting: 41
Growth YoY: +12.6%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (391)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07551544	ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer	withdrawn	Phase 3	0	ImmunityBio, Inc.INDUSTRY	0	May 19, 2026	clinicaltrials
NCT07084909	Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER)	withdrawn	Phase 2 / Phase 3	0	Lantheus Medical ImagingINDUSTRY	1	Dec 10, 2025